Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors

Multi-targeted tyrosine kinase inhibitors (TKIs) have broad efficacy and similar FDA-approved indications, suggesting shared molecular drug targets across cancer types. Irrespective of tumor type, 20-30% of patients treated with multi-targeted TKIs demonstrate intrinsic resistance, with progressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillis, Nancy K., Rotroff, Daniel M., Mesa, Tania E., Yao, Jiqiang, Chen, Zhihua, Carulli, Michael A., Yoder, Sean J., Walko, Christine M., Teer, Jamie K., McLeod, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777758/
https://www.ncbi.nlm.nih.gov/pubmed/29383146
http://dx.doi.org/10.18632/oncotarget.22914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777758/
https://www.ncbi.nlm.nih.gov/pubmed/29383146
http://dx.doi.org/10.18632/oncotarget.22914

Ejemplares similares